# AveXis expands gene therapy manufacturing facility in North Carolina with additional $60M investment

AveXis, a Novartis company, announced an additional $60 million investment and 200 new jobs at its gene therapy manufacturing site in Durham, North Carolina, bringing total investment to $115 million and planned employment to 400. The facility is expected to be completed in the second half of 2020.

- Type: Expansion
- Announced: 2019-02-19
- Where: Durham, North Carolina, United States
- Value: $60.0M
- Jobs: 200
- Starts operating: Q3 2020
- Status: under construction
- Products: gene therapies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [AveXis](https://endata.com/companies/32040.md)
- [Novartis](https://endata.com/companies/32041.md) (investor)

## Sources

- [fiercepharma.com](https://www.fiercepharma.com/manufacturing/novartis-avexis-doubles-down-110m-manufacturing-investment), 2019-02-19: "Continued investment in our infrastructure in North Carolina will allow us to manufacture multiple gene therapies simultaneously, helping us reach more patients, faster."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.